{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-008650","form_type":"8-K","ticker":"HEPA","cik":"0001583771","company_name":"Hepion Pharmaceuticals, Inc.","filed_at":"2026-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.537567+00:00","generated_at":"2026-05-15T22:15:43.151190+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Hepion in-licenses ctRNA biomarker assay for early HCC detection from Cirna Diagnostics","bullets":["Upfront $50K, milestones up to $2.35M, sales milestones up to $4.5M, low single-digit royalty.","Assay detects mutant circulating tumor RNA (ctRNA) for early HCC diagnosis in high-risk cirrhosis patients.","Complements Hepion's mSEPT9 PCR assay; strategic shift to liquid biopsy diagnostics.","Global liquid biopsy market ~$10B; plans CLIA lab partnerships and eventual FDA submission."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-008650","json":"https://secwatch.observer/filing/0001493152-26-008650.json","markdown":"https://secwatch.observer/filing/0001493152-26-008650.md","text":"https://secwatch.observer/filing/0001493152-26-008650.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583771/000149315226008650/0001493152-26-008650-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583771/000149315226008650/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T22:15:43.151190+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5f4128a86efcef46913667d1d4c8e41065a0319f","claim":"Hepion Pharmaceuticals, Inc. entered into intellectual property license agreement with Cirna Diagnostics, LLC valued at upfront payment of $50,000 as well as certain patent expenses, up to $2,350,000 in milestone payment (effective 2026-02-25).","evidence_excerpt":"On February 25, 2026, Hepion Pharmaceuticals, Inc., a Delaware corporation (the “ Company ”), entered into an intellectual property license agreement with Cirna Diagnostics, LLC (“ Cirna ”) pursuant to which the Company licensed certain liver disease diagnostic assets from Cirna.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1583771/000149315226008650/0001493152-26-008650-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Cirna Diagnostics, LLC"},{"label":"Value","value":"upfront payment of $50,000 as well as certain patent expenses, up to $2,350,000 in milestone payment"},{"label":"Effective","value":"2026-02-25"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}